These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25150014)

  • 1. Limited in vitro efficacy of CYP17A1 inhibition on human castration resistant prostate cancer.
    Kosaka T; Miyajima A; Yasumizu Y; Miyazaki Y; Kikuchi E; Oya M
    Steroids; 2014 Dec; 92():39-44. PubMed ID: 25150014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
    Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
    Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity.
    Kosaka T; Miyajima A; Nagata H; Maeda T; Kikuchi E; Oya M
    Sci Rep; 2013; 3():1268. PubMed ID: 23429215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
    Maity SN; Titus MA; Gyftaki R; Wu G; Lu JF; Ramachandran S; Li-Ning-Tapia EM; Logothetis CJ; Araujo JC; Efstathiou E
    Sci Rep; 2016 Oct; 6():35354. PubMed ID: 27748439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
    Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
    Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylated Akt up-regulates angiotensin II type-1 receptor expression in castration resistant prostate cancer.
    Kosaka T; Miyajima A; Shirotake S; Kikuchi E; Oya M
    Prostate; 2011 Oct; 71(14):1510-7. PubMed ID: 21321983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
    de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
    J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
    J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
    Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
    Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
    Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
    J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
    Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
    J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer.
    Toren PJ; Kim S; Pham S; Mangalji A; Adomat H; Guns ES; Zoubeidi A; Moore W; Gleave ME
    Mol Cancer Ther; 2015 Jan; 14(1):59-69. PubMed ID: 25351916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
    Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
    Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial deficiency of 17α-hydroxylase/17,20-lyase caused by a novel missense mutation in the canonical cytochrome heme-interacting motif.
    Rubtsov P; Nizhnik A; Dedov I; Kalinchenko N; Petrov V; Orekhova A; Spirin P; Prassolov V; Tiulpakov A
    Eur J Endocrinol; 2015 May; 172(5):K19-25. PubMed ID: 25650406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
    Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
    Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines.
    Jeong CW; Yoon CY; Jeong SJ; Hong SK; Byun SS; Lee SE
    Korean J Urol; 2011 Jul; 52(7):494-7. PubMed ID: 21860772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP17A1 inhibitors in castration-resistant prostate cancer.
    Gomez L; Kovac JR; Lamb DJ
    Steroids; 2015 Mar; 95():80-7. PubMed ID: 25560485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
    Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
    Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo steroid biosynthesis in human prostate cell lines and biopsies.
    Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
    Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis.
    Udhane SS; Dick B; Hu Q; Hartmann RW; Pandey AV
    Biochem Biophys Res Commun; 2016 Sep; 477(4):1005-1010. PubMed ID: 27395338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.